Cargando…

Molecular signature of adipose tissue in patients with both Non-Alcoholic Fatty Liver Disease (NAFLD) and Polycystic Ovarian Syndrome (PCOS)

BACKGROUND: Polycystic ovarian syndrome (PCOS) is one of the most common reproductive disorders with strong association with both insulin resistance and non-alcoholic fatty liver disease (NAFLD). To untangle the complex relationship between PCOS and NAFLD, we analyzed serum biomarkers of apoptosis,...

Descripción completa

Detalles Bibliográficos
Autores principales: Baranova, Ancha, Tran, Thuy Phuong, Afendy, Arian, Wang, Lei, Shamsaddini, Amirhossein, Mehta, Rohini, Chandhoke, Vikas, Birerdinc, Aybike, Younossi, Zobair M
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2013
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3681627/
https://www.ncbi.nlm.nih.gov/pubmed/23721173
http://dx.doi.org/10.1186/1479-5876-11-133
_version_ 1782273286119358464
author Baranova, Ancha
Tran, Thuy Phuong
Afendy, Arian
Wang, Lei
Shamsaddini, Amirhossein
Mehta, Rohini
Chandhoke, Vikas
Birerdinc, Aybike
Younossi, Zobair M
author_facet Baranova, Ancha
Tran, Thuy Phuong
Afendy, Arian
Wang, Lei
Shamsaddini, Amirhossein
Mehta, Rohini
Chandhoke, Vikas
Birerdinc, Aybike
Younossi, Zobair M
author_sort Baranova, Ancha
collection PubMed
description BACKGROUND: Polycystic ovarian syndrome (PCOS) is one of the most common reproductive disorders with strong association with both insulin resistance and non-alcoholic fatty liver disease (NAFLD). To untangle the complex relationship between PCOS and NAFLD, we analyzed serum biomarkers of apoptosis, some adipokines and mRNA profiles in the visceral adipose tissue of obese patients with NAFLD who were also diagnosed with PCOS and compared to a group with NAFLD only. METHODS: We included patients with biopsy-proven NAFLD and PCOS (N = 12) and BMI-matched biopsy-proven NAFLD patients without PCOS (N = 12). Expression levels of individual mRNAs and soluble serum biomarkers were compared by non-parametric Mann–Whitney test. The analysis also included Spearman rank correlation tests and multiple regression analysis. For co-correlated genes, the factor analysis was performed. RESULTS: The total serum levels of apoptotic biomarker M30 were significantly elevated in PCOS patients with liver steatosis as compared to non-PCOS NAFLD controls (P < 0.02), pointing that androgen-dependent proapoptotic PCOS environment that may directly contribute to NAFLD progression in these patients. Similarly, hyperandrogenism may explain the observed PCOS-specific decrease (P < 0.04) in adipose LDLR mRNA expression that may be connected to the proneness of PCOS patients to NAFLD. The levels of mRNA encoding angiogenesis-associated GSK-3B interacting protein ninein were also significantly increased in the adipose tissue of NAFLD patients with PCOS (P < 0.007). Furthermore, the levels of resistin positively correlated with expression levels of LDLR and prothrombin time (PT). CONCLUSION: An androgen-dependent proapoptotic PCOS environment may directly contribute to NAFLD progression in these patients. Hyperandrogenism may explain an observed decrease in adipose LDLR mRNA expression. An inflammation-associated increase in the release of resistin into circulation might contribute to the prothrombotic state observed under conditions associated with insulin resistance, including PCOS. The studies of larger cohorts of NAFLD with and without PCOS patients are needed to further assess these potential interactions.
format Online
Article
Text
id pubmed-3681627
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-36816272013-06-14 Molecular signature of adipose tissue in patients with both Non-Alcoholic Fatty Liver Disease (NAFLD) and Polycystic Ovarian Syndrome (PCOS) Baranova, Ancha Tran, Thuy Phuong Afendy, Arian Wang, Lei Shamsaddini, Amirhossein Mehta, Rohini Chandhoke, Vikas Birerdinc, Aybike Younossi, Zobair M J Transl Med Research BACKGROUND: Polycystic ovarian syndrome (PCOS) is one of the most common reproductive disorders with strong association with both insulin resistance and non-alcoholic fatty liver disease (NAFLD). To untangle the complex relationship between PCOS and NAFLD, we analyzed serum biomarkers of apoptosis, some adipokines and mRNA profiles in the visceral adipose tissue of obese patients with NAFLD who were also diagnosed with PCOS and compared to a group with NAFLD only. METHODS: We included patients with biopsy-proven NAFLD and PCOS (N = 12) and BMI-matched biopsy-proven NAFLD patients without PCOS (N = 12). Expression levels of individual mRNAs and soluble serum biomarkers were compared by non-parametric Mann–Whitney test. The analysis also included Spearman rank correlation tests and multiple regression analysis. For co-correlated genes, the factor analysis was performed. RESULTS: The total serum levels of apoptotic biomarker M30 were significantly elevated in PCOS patients with liver steatosis as compared to non-PCOS NAFLD controls (P < 0.02), pointing that androgen-dependent proapoptotic PCOS environment that may directly contribute to NAFLD progression in these patients. Similarly, hyperandrogenism may explain the observed PCOS-specific decrease (P < 0.04) in adipose LDLR mRNA expression that may be connected to the proneness of PCOS patients to NAFLD. The levels of mRNA encoding angiogenesis-associated GSK-3B interacting protein ninein were also significantly increased in the adipose tissue of NAFLD patients with PCOS (P < 0.007). Furthermore, the levels of resistin positively correlated with expression levels of LDLR and prothrombin time (PT). CONCLUSION: An androgen-dependent proapoptotic PCOS environment may directly contribute to NAFLD progression in these patients. Hyperandrogenism may explain an observed decrease in adipose LDLR mRNA expression. An inflammation-associated increase in the release of resistin into circulation might contribute to the prothrombotic state observed under conditions associated with insulin resistance, including PCOS. The studies of larger cohorts of NAFLD with and without PCOS patients are needed to further assess these potential interactions. BioMed Central 2013-05-31 /pmc/articles/PMC3681627/ /pubmed/23721173 http://dx.doi.org/10.1186/1479-5876-11-133 Text en Copyright © 2013 Baranova et al.; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research
Baranova, Ancha
Tran, Thuy Phuong
Afendy, Arian
Wang, Lei
Shamsaddini, Amirhossein
Mehta, Rohini
Chandhoke, Vikas
Birerdinc, Aybike
Younossi, Zobair M
Molecular signature of adipose tissue in patients with both Non-Alcoholic Fatty Liver Disease (NAFLD) and Polycystic Ovarian Syndrome (PCOS)
title Molecular signature of adipose tissue in patients with both Non-Alcoholic Fatty Liver Disease (NAFLD) and Polycystic Ovarian Syndrome (PCOS)
title_full Molecular signature of adipose tissue in patients with both Non-Alcoholic Fatty Liver Disease (NAFLD) and Polycystic Ovarian Syndrome (PCOS)
title_fullStr Molecular signature of adipose tissue in patients with both Non-Alcoholic Fatty Liver Disease (NAFLD) and Polycystic Ovarian Syndrome (PCOS)
title_full_unstemmed Molecular signature of adipose tissue in patients with both Non-Alcoholic Fatty Liver Disease (NAFLD) and Polycystic Ovarian Syndrome (PCOS)
title_short Molecular signature of adipose tissue in patients with both Non-Alcoholic Fatty Liver Disease (NAFLD) and Polycystic Ovarian Syndrome (PCOS)
title_sort molecular signature of adipose tissue in patients with both non-alcoholic fatty liver disease (nafld) and polycystic ovarian syndrome (pcos)
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3681627/
https://www.ncbi.nlm.nih.gov/pubmed/23721173
http://dx.doi.org/10.1186/1479-5876-11-133
work_keys_str_mv AT baranovaancha molecularsignatureofadiposetissueinpatientswithbothnonalcoholicfattyliverdiseasenafldandpolycysticovariansyndromepcos
AT tranthuyphuong molecularsignatureofadiposetissueinpatientswithbothnonalcoholicfattyliverdiseasenafldandpolycysticovariansyndromepcos
AT afendyarian molecularsignatureofadiposetissueinpatientswithbothnonalcoholicfattyliverdiseasenafldandpolycysticovariansyndromepcos
AT wanglei molecularsignatureofadiposetissueinpatientswithbothnonalcoholicfattyliverdiseasenafldandpolycysticovariansyndromepcos
AT shamsaddiniamirhossein molecularsignatureofadiposetissueinpatientswithbothnonalcoholicfattyliverdiseasenafldandpolycysticovariansyndromepcos
AT mehtarohini molecularsignatureofadiposetissueinpatientswithbothnonalcoholicfattyliverdiseasenafldandpolycysticovariansyndromepcos
AT chandhokevikas molecularsignatureofadiposetissueinpatientswithbothnonalcoholicfattyliverdiseasenafldandpolycysticovariansyndromepcos
AT birerdincaybike molecularsignatureofadiposetissueinpatientswithbothnonalcoholicfattyliverdiseasenafldandpolycysticovariansyndromepcos
AT younossizobairm molecularsignatureofadiposetissueinpatientswithbothnonalcoholicfattyliverdiseasenafldandpolycysticovariansyndromepcos